NCT02828319已完成3 期
Clinical Study of Z-213 in Subjects With Iron-deficiency Anemia
Zeria Pharmaceutical0 个研究点目标入组 39 人开始时间: 2016年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 39
- 主要终点
- Number of participants with Adverse Drug Reactions
研究概览
简要总结
To confirm the safety and efficacy of Z-213 until 12 weeks after start of Z-213 administration in patients with iron deficiency Anemia
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with iron deficiency anemia
排除标准
- •Patients with anemia caused by conditions other than iron deficiency
- •Patients with abnormal laboratory test values at screening for Serum phosphorus, Aspartate aminotransferase, Alanine aminotransferase
- •Patients with liver, kidney or circulatory system disease
- •Patients with a history or present illness that is a malignant tumor or autoimmune disease
- •Patients who underwent intravenous administration of an iron preparation, administration of an erythropoiesis stimulation agent or blood transfusion within 8 weeks before the screening
- •Patients who underwent oral administration of an iron preparation (including an over-the-counter drug or supplement) within 4 weeks before the screening
研究组 & 干预措施
Z-213
Experimental
干预措施: Z-213 (Drug)
结局指标
主要结局
Number of participants with Adverse Drug Reactions
时间窗: 12 weeks
Number of participants with Adverse Events
时间窗: 12 weeks
次要结局
- Maximum change in Hb value(12 weeks)
- Change in Hb value(12 weeks)
- Proportion of responders(12 weeks)
- Proportion of subjects with normalization in Hb value(12 weeks)
- Proportion of cumulative dosage(12 weeks)
- Number of doses to total dose achieved(12 weeks)
- Time to total dose achieved(12 weeks)
研究者
相似试验
已完成
1 期
Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency AnemiaIron Deficiency AnemiaNCT02170311Zeria Pharmaceutical24
已完成
3 期
Efficacy Study of Intravenous Iron Preparation to Iron Deficiency AnemiaIron Deficiency AnemiaNCT02731534Zeria Pharmaceutical238
已完成
不适用
Zinc Supplementation and Severe and Recurrent DiarrheaDiarrheaNCT01306097Hormozgan University of Medical Sciences100
已完成
4 期
Study of Zinc for Wilson DiseaseWilson DiseaseNCT00004338National Center for Research Resources (NCRR)300
已完成
3 期
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKDAnemia of Chronic Kidney DiseaseNCT04543812Panion & BF Biotech Inc.141